Tradestie Institutional Equity Comparison Engine

CDT vs NIVF โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CDT Overall Edge

CDT Captures Institutional Edge (2โ€“0 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CDT Equity Inc. Common Stock (CDT) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, CDT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NIVF at N/M Forward P/E and -238.2% operating margin (-4.7% YoY). In options structure, CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against NIVF sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CDT N/M vs NIVF N/M Fwd P/E
Growth & Margin Winner CDT
Op Margin 0.0% vs -238.2% ยท YoY +0.0% vs -4.7%
Momentum & Technical Winner CDT
1Y -86.8% vs -91.8% ยท 52W Pos 2% vs 0%
Options & Structure Winner Tie
BREAKDOWN (N/A IV) vs BREAKDOWN (N/A IV)
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
NIVF NASDAQ
NewGenIvf Group Limited Class A ordinary shares
Services-Misc Health & Allied Services, Nec
$0.03
-23.14% 1D
Market Cap $98,000
1M Return -81.93%
1Y Return -91.82%
Forward P/E N/M
Unified AI Score
47.7 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CDT -86.78% NIVF -91.82% Spread: +5.04 pp (CDT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CDT TTM Op. Margin: 0.0% NIVF TTM Op. Margin: -238.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs NIVF. Trailing 12-month operating profitability (CDT 0.0% vs NIVF -238.2%) and valuation multiples (CDT N/M vs NIVF N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CDT (3) vs NIVF (4)
Institutional Metric CDT NIVF Criterion Row Winner
Market Capitalization Scale $507,528 $98,000 Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -4.7% Higher Growth CDT
Operating Margin (TTM) Profitability 0.0% -238.2% Higher Margin CDT
Net Profit Margin Profitability 0.0% 24.2% Higher Margin NIVF
Return on Equity (ROE) Capital Efficiency -69.7% 5.5% Higher ROE NIVF
52-Week Range Position Momentum 2% ($0โ€“$11) 0% ($0โ€“$3) Stronger Trend CDT
Beta / 30D Volatility Risk Regime -17.75ฮฒ ยท 10175% Vol 0.05ฮฒ ยท 3040% Vol Lower Realized Risk NIVF
Unified Institutional Score Composite Signal 31.6 / 100 (SELL) 47.7 / 100 (HOLD) Higher Composite NIVF

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CDT vs NIVF Buy Guide
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NIVF BREAKDOWN
19d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NIVF Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CDT nor NIVF registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.